Trial Profile
A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary) ; Paclitaxel (Primary) ; Epirubicin
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 28 Mar 2023 Planned End Date changed from 1 Jul 2022 to 1 Jul 2041.
- 28 Mar 2023 Status changed from suspended to active, no longer recruiting.
- 20 Sep 2021 Status changed from recruiting to suspended.